FTSE MIB
25.892,18 -590,03 (-2,23%) Dow Jones
32.237,53 +132,28 (+0,41%) Nasdaq
11.823,96 +36,56 (+0,31%) Nikkei 225
27.385,25 -34,36 (-0,13%) Petrolio
69,20 -0,76 (-1,09%) Bitcoin EUR
25.726,14 +241,17 (+0,95%)
Codexis, Inc. (CDXS)
Dopo ore:
| Chiusura precedente | 3,8700 |
| Aperto | 3,8200 |
| Denaro | 3,7500 x 1200 |
| Lettera | 3,8900 x 1400 |
| Min-Max giorno | 3,7950 - 3,9500 |
| Intervallo di 52 settimane | 3,7900 - 22,2200 |
| Volume | |
| Media Volume | 654.721 |
| Capitalizzazione | 255,874M |
| Beta (5 anni mensile) | 1,63 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,5100 |
| Prossima data utili | 03 mag 2023 - 08 mag 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 12,88 |
- GlobeNewswire
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 43,403 shares of Codexis’ common stock and (ii) restricted stock units (RSUs) for 9,723 shares of Codexis common stock as induceme
- GlobeNewswire
Codexis to Participate in Cowen 43rd Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, will participate in a panel discussion titled, “SynBio & AI Driven Drug Discovery,” taking place on Mo
- GlobeNewswire
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Provides 2023 Revenue Guidance REDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a busine
